142 related articles for article (PubMed ID: 32648839)
1. Evaluation of Variances in VEGF-A-D and VEGFR-1-3 Expression in the Ishikawa Endometrial Cancer Cell Line Treated with Salinomycin and Anti-Angiogenic/Lymphangiogenic Effect.
Kras P; Talkowski K; Grabarek BO; Skalska-Dziobek N; Boroń D; Oplawski M
Curr Pharm Biotechnol; 2021; 22(5):697-705. PubMed ID: 32648839
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Differences in the Expression of mRNAs and miRNAs Associated with Drug Resistance in Endometrial Cancer Cells Treated with Salinomycin.
Januszyk P; Januszyk K; Wierzbik-Strońska M; Boroń D; Grabarek B
Curr Pharm Biotechnol; 2021; 22(4):541-548. PubMed ID: 32598254
[TBL] [Abstract][Full Text] [Related]
3. Salinomycin Modulates the Expression of mRNAs and miRNAs Related to Stemness in Endometrial Cancer.
Talkowski K; Kiełbasiński K; Peszek W; Grabarek BO; Boroń D; Oplawski M
Curr Pharm Biotechnol; 2021; 22(2):317-326. PubMed ID: 32564748
[TBL] [Abstract][Full Text] [Related]
4. Effect of Salinomycin on Expression Pattern of Genes Associated with Apoptosis in Endometrial Cancer Cell Line.
Kiełbasiński K; Peszek W; Grabarek BO; Boroń D; Wierzbik-Strońska M; Oplawski M
Curr Pharm Biotechnol; 2020; 21(12):1269-1277. PubMed ID: 32400328
[TBL] [Abstract][Full Text] [Related]
5. A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 "multi-points priming" mechanisms in vitro and in vivo.
Li XP; Jing W; Sun JJ; Liu ZY; Zhang JT; Sun W; Zhu W; Fan YZ
BMC Cancer; 2015 Jul; 15():527. PubMed ID: 26187792
[TBL] [Abstract][Full Text] [Related]
6. Expression Profile of VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer.
Oplawski M; Dziobek K; Zmarzły N; Grabarek B; Halski T; Januszyk P; Kuś-Kierach A; Adwent I; Dąbruś D; Kiełbasiński K; Boroń D
Curr Pharm Biotechnol; 2019; 20(12):1004-1010. PubMed ID: 31333122
[TBL] [Abstract][Full Text] [Related]
7. The Influence of Salinomycin on the Expression Profile of mRNAs Encoding Selected Caspases and MiRNAs Regulating their Expression in Endometrial Cancer Cell Line.
Januszyk K; Januszyk P; Grabarek BO; Boroñ D; Oplawski M
Curr Pharm Biotechnol; 2020; 21(14):1505-1515. PubMed ID: 32407273
[TBL] [Abstract][Full Text] [Related]
8. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
10. High Glucose Promotes Epithelial-Mesenchymal Transition of Uterus Endometrial Cancer Cells by Increasing ER/GLUT4-Mediated VEGF Secretion.
Gu CJ; Xie F; Zhang B; Yang HL; Cheng J; He YY; Zhu XY; Li DJ; Li MQ
Cell Physiol Biochem; 2018; 50(2):706-720. PubMed ID: 30308493
[TBL] [Abstract][Full Text] [Related]
11. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.
Lohela M; Bry M; Tammela T; Alitalo K
Curr Opin Cell Biol; 2009 Apr; 21(2):154-65. PubMed ID: 19230644
[TBL] [Abstract][Full Text] [Related]
12. Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer.
Dziobek K; Opławski M; Grabarek BO; Zmarzły N; Tomala B; Halski T; Leśniak E; Januszyk K; Brus R; Kiełbasiński R; Boroń D
Curr Pharm Biotechnol; 2019; 20(11):955-963. PubMed ID: 31322068
[TBL] [Abstract][Full Text] [Related]
13. Lymphangiogenic growth factors, receptors and therapies.
Lohela M; Saaristo A; Veikkola T; Alitalo K
Thromb Haemost; 2003 Aug; 90(2):167-84. PubMed ID: 12888864
[TBL] [Abstract][Full Text] [Related]
14. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
15. Molecular profile and proliferative responses of rat lymphatic endothelial cells in culture.
Whitehurst B; Eversgerd C; Flister M; Bivens CM; Pickett B; Zawieja DC; Ran S
Lymphat Res Biol; 2006; 4(3):119-42. PubMed ID: 17034293
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
[TBL] [Abstract][Full Text] [Related]
17. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
18. 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model.
Hwang-Bo J; Bae MG; Park JH; Chung IS
BMC Cancer; 2018 Jul; 18(1):714. PubMed ID: 29976150
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor-D over-expressing tumor cells induce differential effects on uterine vasculature in a mouse model of endometrial cancer.
Girling JE; Donoghue JF; Lederman FL; Cann LM; Achen MG; Stacker SA; Rogers PA
Reprod Biol Endocrinol; 2010 Jul; 8():84. PubMed ID: 20615255
[TBL] [Abstract][Full Text] [Related]
20. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.
Underiner TL; Ruggeri B; Gingrich DE
Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
